Company: NIVFW
Filing Date: 2025-08-21
Form Type: DRS
Source: 0001213900-25-079301
Chunk: 19

Company: NewGenIvf Group Ltd
Filing Date: 2025-08-21
Form: DRS
Chunk 19
---
 global market beyond Asia Pacific, NewGenIvf intends to expand its footprint through partnerships with other IVF clinics.

<div align='center'>6</div>

In addition, NewGenIvf plans
to explore expanding its client base by offering its fertility services as part of corporate benefit programs in Asia. NewGenIvf believes
that there is potential in Asia in offering fertility treatments as a benefit for employees, particularly in companies with a large number
of female employees of childbearing age. By partnering with corporate clients to provide fertility benefits, NewGenIvf can increase its
market reach, enhance its brand reputation, and drive client growth. NewGenIvf’s broad range of fertility services, including IVF
and egg freezing, can help corporate partners differentiate their employee benefits in the competitive employment landscape, which could
make them more attractive to potential employees. Additionally, by offering these services, companies can help address the growing concern
of delayed childbearing, which is becoming more common among women according to CIC. NewGenIvf plans to collaborate with potential
corporate clients to develop customized fertility benefit programs that cater to their specific needs, and to provide comprehensive support
and counselling throughout the process.

Meanwhile, NewGenIvf also
intends to attract more clients by establishing its “home country gynecologist partnership program”. Under the program, NewGenIvf
may, subject to its discretion and screening process, offer treatment services to clients with reduced time requirements to be spent overseas.
Depending on local laws, the potential clients may be able to complete their treatments with gynecologists NewGenIvf partners with, in
their home countries.

NewGenIvf had entered into
a non-binding term sheet dated June 3, 2024 (the “Term Sheet”) with COVIRIX Medical Pty Ltd (“COVIRIX”) for a
proposed reverse merger (the “COVIRIX “Proposed Transaction”). However, on September 21, 2024, COVIRIX withdrew from
the Proposed Transaction, as such the Proposed Transaction was terminated with no cost to the Company. On December 11,
2024, NewGenIvf also announced its entry into a binding term sheet with European Wellness Investment Holdings Limited (“EWIHL”)
for a proposed reverse merger (“EWIHL Proposed Transaction”), completion of which was subject to, among other conditions,
the completion of due diligence, the negotiation of a definitive agreement, and obtaining adequate financing. On March 31, 202